269 related articles for article (PubMed ID: 30483765)
1. AngiomiRs: MicroRNAs driving angiogenesis in cancer (Review).
Salinas-Vera YM; Marchat LA; Gallardo-Rincón D; Ruiz-García E; Astudillo-De La Vega H; Echavarría-Zepeda R; López-Camarillo C
Int J Mol Med; 2019 Feb; 43(2):657-670. PubMed ID: 30483765
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
3. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
4. New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications.
Wang Y; Wang L; Chen C; Chu X
Mol Cancer; 2018 Feb; 17(1):22. PubMed ID: 29415727
[TBL] [Abstract][Full Text] [Related]
5. MicroRNAs: promising new antiangiogenic targets in cancer.
Gallach S; Calabuig-Fariñas S; Jantus-Lewintre E; Camps C
Biomed Res Int; 2014; 2014():878450. PubMed ID: 25197665
[TBL] [Abstract][Full Text] [Related]
6. Regulation of tumor angiogenesis by microRNAs: State of the art.
Goradel NH; Mohammadi N; Haghi-Aminjan H; Farhood B; Negahdari B; Sahebkar A
J Cell Physiol; 2019 Feb; 234(2):1099-1110. PubMed ID: 30070704
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs in tumor angiogenesis.
Wang W; Zhang E; Lin C
Life Sci; 2015 Sep; 136():28-35. PubMed ID: 26144623
[TBL] [Abstract][Full Text] [Related]
8. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
Gacche RN; Meshram RJ
Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
Huang Y; Carbone DP
Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA Key to Angiogenesis Regulation: MiRNA Biology and Therapy.
Tiwari A; Mukherjee B; Dixit M
Curr Cancer Drug Targets; 2018; 18(3):266-277. PubMed ID: 28669338
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics.
Fuso Nerini I; Cesca M; Bizzaro F; Giavazzi R
Chin J Cancer; 2016 Jun; 35(1):61. PubMed ID: 27357621
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
16. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
18. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
19. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
20. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
